Aquestive Therapeutics, Inc. announced the appointment of Mark Lepore, MD, as the Chief Medical Officer for Allergy. Dr. Lepore is a board-certified allergist and pediatrician. He has over fourteen years of drug development experience, including serving as Vice President, Head of Clinical Strategy and Development for Inhalation and Complex Injectable Products, and Vice President, Global Clinical Development, at Lupin Pharmaceuticals, Inc., and previous clinical research roles in respiratory therapeutics at Teva Pharmaceuticals. Prior to joining industry, Dr. Lepore spent over a decade in private practice as an allergy and asthma specialist and served as a clinical investigator in over one hundred industry-sponsored trials. He received his medical training at Thomas Jefferson University.